Your browser doesn't support javascript.
Harnessing autophagy to fight SARS-CoV-2: An update in view of recent drug development efforts.
Rein, Theo.
  • Rein T; Department of Translational Research in Psychiatry, Max Planck Institute of Psychiatry, Munich, Germany.
J Cell Biochem ; 123(2): 155-160, 2022 02.
Article in English | MEDLINE | ID: covidwho-1473858
ABSTRACT
Drug repurposing is an attractive option for identifying new treatment strategies, in particular in extraordinary situations of urgent need such as the current coronavirus disease 2019 (Covid-19) pandemic. Recently, the World Health Organization announced testing of three drugs as potential Covid-19 therapeutics that are known for their dampening effect on the immune system. Thus, the underlying concept of selecting these drugs is to temper the potentially life-threatening overshooting of the immune system reacting to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. This viewpoint discusses the possibility that the impact of these and other drugs on autophagy contributes to their therapeutic effect by hampering the SARS-CoV-2 life cycle.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Autophagy / Drug Repositioning / Pandemics / Imatinib Mesylate / Infliximab / Artesunate / SARS-CoV-2 / COVID-19 Drug Treatment Type of study: Prognostic study Limits: Humans Language: English Journal: J Cell Biochem Year: 2022 Document Type: Article Affiliation country: Jcb.30166

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Autophagy / Drug Repositioning / Pandemics / Imatinib Mesylate / Infliximab / Artesunate / SARS-CoV-2 / COVID-19 Drug Treatment Type of study: Prognostic study Limits: Humans Language: English Journal: J Cell Biochem Year: 2022 Document Type: Article Affiliation country: Jcb.30166